Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Advanced Type 2 Diabetes
Authors not listed
Yonsei University · 2023
Abstract
Patients with type 2 diabetes (T2D) are more prevalent with aging-related comorbidities and frailty, which leads to a shorter life expectancy than non-diabetic individuals and that this excess mortality is largely attributable to cardiovascular causes.
Therefore, since diabetes accelerates cellular senescence(definition), attenuating aging process in patients with T2D is expected to reduce progression of comorbidities and eventually increase lifespan.
According to previous studies, sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown increased ketone bodies not only in blood but in various tissues including liver, kidney and colon, which could lead to beneficial effects in metabolic diseases. Especially, β-hydroxybutyrate (βHB) inhibits oxidative stress and reduces insulin resistance, which has a positive effect on preventing cardio-renal-metabolic diseases and aging process in patients with T2D.
In this context, SGLT2 inhibitor can be a promising option to alleviate senescence process in patients with T2D. However, despite the accumulating evidence that support anti-senescent effect of SGLT2 inhibitor in preclinical models, no clinical study has investigated association between SGLT2 inhibitor use and senescence patients with T2D.
Thus, the objective of this study is to determine whether the use of SGLT2 inhibitor is associated with anti-senescent effect in patients with T2D, which may expand the indications of SGLT2 inhibitor other than glycemic control.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-01 MST
Cite this
APA
Anonymous. (2023). Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Advanced Type 2 Diabetes. <em>Yonsei University</em>. https://clinicaltrials.gov/study/NCT05975528
Vancouver
Anonymous. Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Advanced Type 2 Diabetes. Yonsei University. 2023.
BibTeX
@misc{anon2023Effect,
title = {Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Advanced Type 2 Diabetes},
author = {Anonymous},
journal = {Yonsei University},
year = {2023},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Clinical and Experimental Dermatology 2025
Citation only
Looking beyond chronological age: the importance of frailty in biologic treatment efficacy in older individuals
Aging and Disease 2026
Open access · CC-BY
Oral Dysbiosis and the Hallmarks of Aging: A Perspective on Mechanisms and Therapeutic Opportunities
European journal of medical research 2023
Open access · CC-BY
Association of metformin exposure with low risks of frailty and adverse outcomes in patients with diabetes
Diabetes Care 2018
Open access · OA
The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study)
Azienda Policlinico Umberto I 2019
Open access · US-GOV
A Randomized, Double Blind Placebo Controlled Clinical Trial to Assess the Efficacy and Safety of Sitagliptin on Bone Measures in Women Affected by Type 2 Diabetes. a Gender-oriented Approach to Address a Gender-specific Frailty: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) Study.
University of Wisconsin, Madison 2017
Open access · US-GOV